Nicholas Gurney, MD
Glaucoma Specialist · Ft Worth, TXNPI 1831650639
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Bausch & Lomb Americas Inc. accounts for 67.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $8,793 and has fallen 83.1% since, to $1,482 in 2025.
Across 71 payments — averaging $181.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$9K
- Alcon$1K
- Glaukos Corporation$912
- NEW World Medical,inc.$704
- AbbVie$628
- Sight Sciences, Inc.$494
- plus $182 from 2 others
What the payments were for
- Consulting fees$5,75045%
- Travel & lodging$2,42819%
- Food & beverage$4,72737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 23 | $8,707 |
| Alcon | 11 | $1,278 |
| Glaukos Corporation | 10 | $912 |
| NEW World Medical,inc. | 8 | $704 |
| AbbVie | 7 | $628 |
| Sight Sciences, Inc. | 8 | $494 |
| Genentech USA, Inc. | 1 | $123 |
| Ocular Therapeutix, Inc. | 3 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$8,140
- enVista MX60 IOL$8,140
- Trulign IOL$8,140
- Crystalens Accommodating IOL (AT-52AO)$8,140
- Clareon$649
- Hydrus Microstent$411
- OMNI(R) SURGICAL SYSTEM (US)$403
- DURYSTA$372
- iStent Infinite$289
- iDoseTR$289
- iDose$170
- Kahook Dual Blade$152
- Clearpath$152
- Ahmed Glaucoma Valve$152
- Streamline$152
- SION SURGICAL INSTRUMENT$145
- XEN GLAUCOMA TREATMENT SYSTEM$123
- VABYSMO$123
- STELLARIS$122
How this compares
$12,905 in reported general payments places this provider in the 85th percentile of 31 glaucoma specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 46 | $16,824 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $12,405 |
| RhopressaNetarsudil Mesylate | 24 | $12,272 |
| Methazolamide | 44 | $10,952 |
| Brinzolamide | 45 | $5,035 |
| Travoprost | 24 | $4,870 |
| Prednisolone Acetate | 102 | $4,542 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 12 | $3,154 |
| Latanoprost | 234 | $2,445 |
| Ketorolac Tromethamine | 61 | $2,152 |
| Dorzolamide Hcl | 104 | $2,097 |
| Brimonidine Tartrate | 88 | $2,092 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 133 | $1,851 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,659 |
| Timolol Maleate | 176 | $1,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $628 | $29,22981 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 31 glaucoma specialist providers in Texas.
Other glaucoma specialist in Ft Worth
- Shivani KamatDallas$164K
- Robert FeldmanHouston$31K
- Amenze OriaifoAustin$18K
- David LeeHouston$17K
- Patrick WuHouston$11K
- Irina VoloskoAustin$11K
- Logan VincentTyler$5K
- Thao ThachGarland$4K
- Elza RachidHouston$4K
- Adam VandenlangenbergHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.